Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease.

Arteriosclerosis, thrombosis, and vascular biology - 1 Jun 2002

Herrington David M, Vittinghoff Eric, Howard Timothy D, Major David A, Owen John, Reboussin David M, Bowden Donald, Bittner Vera, Simon Joel A, Grady Deborah, Hulley Stephen B

Abstract excerpt

Oral contraceptive use in women with factor V Leiden is associated with increased rates of venous thromboembolic events (VTEs). However, the effects of hormone replacement therapy (HRT) in postmenopausal women with factor V Leiden are not known. A nested case-control study was conducted among women with established coronary disease enrolled in 2 randomized clinical trials of HRT, the Heart and Estrogen/Progestin...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Coronary Disease
Share to Factor V

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hormone Replacement Therapy

Share to Multicenter Studies as Topic

Share to Randomized Controlled Trials as Topic

Share to Thromboembolism

Share to Venous Thrombosis

Source

Identifiers

PMID: 12067913
DOI: 10.1161/01.atv.0000018301.91721.94

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease.PMID 12067913Read ↗

Oral contraceptives, hormone therapy and cardiovascular risk.Semantic proximity Read ↗

Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration.Semantic proximity Read ↗

Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis.Semantic proximity Read ↗

Prothrombotic mutations, family history and the risk of thrombosis in postmenopausal women: implications for hormone replacement therapy.Semantic proximity Read ↗

Estrogen replacement therapy, thrombophilia, and atherothrombosis.Semantic proximity Read ↗

Influence of coronary artery disease-associated genetic variants on risk of venous thromboembolism.Semantic proximity Read ↗

HORMONE EXPOSURE AND VENOUS THROMBOEMBOLISM IN COMMERCIALLY-INSURED WOMEN 50 TO 64 YEARS OF AGESemantic proximity Read ↗

Estrogen therapy and thrombotic risk.Semantic proximity Read ↗

A prospective study of venous thromboembolism in relation to factor V Leiden and related factors.Semantic proximity Read ↗

Interaction of estrogen replacement therapy with the thrombophilic 20210 G/A prothrombin gene mutation for atherothrombotic vascular disease: a cross-sectional study of 275 hyperlipidemic women.Semantic proximity Read ↗

Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women.Semantic proximity Read ↗

The effect of prothrombotic blood abnormalities on risk of deep vein thrombosis in users of hormone replacement therapy: a prospective case-control study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.